TRML
Tourmaline Bio, Inc.
$47.98
+0.00
(+0.00%)
Mkt Cap
1.23B
Volume
783,730
52W Range
11.56-48.27
Sector
Healthcare
Beta
1.58
EPS (TTM)
-3.43
P/E Ratio
-7.02
Revenue (TTM)
40,000
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (73.21M) | (42.12M) | (19.70M) | (904) | (22.71M) | (18.16M) |
| EPS | -2.89 | -8.87 | -0.97 | -0.00 | -33.97 | -4.39 |
| Free Cash Flow | (77.27M) | (28.14M) | (11.53M) | (42.42M) | (20.50M) | (18.22M) |
| FCF / Share | -3.05 | -5.93 | -0.57 | -3.90 | -30.66 | -4.41 |
| Operating CF | (77.26M) | (28.08M) | (6.46M) | (39.99M) | (19.21M) | (17.66M) |
| Total Assets | 309.00M | 210.29M | 9.10M | 251.42M | 152.78M | 41.94M |
| Total Debt | 244,000 | 415,000 | 504,000 | 0 | 0 | 0 |
| Cash & Equiv | 30.51M | 140.73M | 8.26M | 18.61M | 17.59M | 38.98M |
| Book Value | 300.05M | 205.04M | (19.73M) | 242.81M | 148.00M | 39.59M |
| Return on Equity | -0.24 | -0.21 | N/A | -0.00 | -0.15 | -0.46 |
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 40,000 | 0 | 0 | 0 | 2.28M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.09M) | (22.97M) | (22.23M) | (20.18M) | (17.49M) | (13.31M) | (12.90M) | (7.01M) | (16.13M) | (7.50M) | (4,920) | (1,955) |
| EPS | -0.90 | -0.89 | -0.86 | -0.78 | -0.68 | -0.55 | -0.81 | -0.34 | -1.30 | -0.37 | -0.00 | -0.00 |
| Free Cash Flow | (20.27M) | (21.69M) | (20.90M) | (23.44M) | (18.01M) | (14.92M) | 11.02M | (26.27M) | (9.55M) | (3.81M) | (2.30M) | (13.77M) |
| FCF / Share | -0.79 | -0.84 | -0.81 | -0.91 | -0.70 | -0.62 | 0.69 | -1.29 | -0.77 | -0.19 | -0.21 | -1.27 |
| Operating CF | (20.26M) | (21.68M) | (20.89M) | (23.44M) | (18.01M) | (14.92M) | 11.02M | (25.77M) | (9.54M) | (3.79M) | (4,497) | (13.43M) |
| Total Assets | 269.30M | 287.50M | 309.00M | 328.45M | 344.79M | 359.17M | 210.29M | 151.06M | 91.61M | 172.61M | 9.10M | 206.54M |
| Total Debt | 145,000 | 196,000 | 244,000 | 290,000 | 333,000 | 376,000 | 415,000 | 634,000 | 489,000 | 1.27M | 504,000 | 3.10M |
| Cash & Equiv | 31.42M | 35.33M | 30.51M | 35.01M | 70.15M | 98.29M | 140.73M | 67.08M | 87.09M | 24.22M | 8.26M | 18.47M |
| Book Value | 259.19M | 279.86M | 300.05M | 321.07M | 338.28M | 354.14M | 205.04M | 142.87M | (42.53M) | 161.73M | (19.73M) | 194.87M |
| Return on Equity | -0.09 | -0.08 | -0.07 | -0.06 | -0.05 | -0.04 | -0.06 | -0.05 | N/A | -0.05 | N/A | -0.00 |
TRML News
No news available for TRML.